摘要
为了确定病毒唑在流行性出血热(EHF)患者体内对流行性出血热病毒(EHFV)的清除作用,我们对52例EHFIgM阳性和病毒分离阳性的EHF患者进行了病毒血症的动态检测。在治疗开始后第3天,病毒血症检出率在病毒唑组与安慰剂组无差异,两组各为48士2.8和68士3.0%(P>0.05);但病毒抗原量和病毒感染性滴度,两组各为0.6士0.24、0.71士0.28OD和3.2士0.43、4.2士0.54TCIDe/ml(P<0.05)。病毒血症平均持续时间两组各为3.6t0.2和6.9士0.6天;在治疗后第8天,病毒唑组患者病毒血症消失,安慰剂组在第17天消失。这一结果说明用药3天不足以消除患者的病毒血症,并就药物剂量与疗程问题进行了讨论。
In order to confirm the anti-hantanvirus therapeutic effect of ribavirin in epidemlehemorrhagic fever(EHF)patiente,dynamic change of viremia were observed in 52 casesof EHF in whom ribavirin was adminstered with double blind randomized controlstudies EHF IgM and virus isolation were all positive.The viremis detection rate wasidentical in both groupa on day 3 of treatment,the rate is 48+2.8 and 68+3.0%respo-ctively(P>0.05).But the viral antigen amount and virus infectivity titer of théribaviringroup was lower than that of the placebo controlled group,the valuo is 0:6+0.24 and0.71+0.28(OD value)3.2+0.43 and 4.2+0.54(TOID50/0.1ml)than that in the placebocontrolled group(6.9+0.6 dayg).Viremta disappeared on day 8 in ribavirin group andon day 17 in placebo controlled group.The resulta showed that viremis of EHF patientscan not be elliminated by 3 day therapy.Dosage and course of ribavirin treatment arsdiscussed.
出处
《中华传染病杂志》
CAS
CSCD
北大核心
1993年第1期30-33,共4页
Chinese Journal of Infectious Diseases
基金
美国陆军传染病研究所资助。
关键词
流行性出血热
病毒
病毒唑
治疗
Epidemic hemorrhagic fever
Viremia
Ribavirin
